Jasper Therapeutics (NASDAQ:JSPR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a research report released on Saturday.

JSPR has been the subject of several other reports. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Finally, TD Cowen cut shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Hold” and an average price target of $12.00.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $0.69 on Friday. The stock has a 50-day simple moving average of $0.61 and a 200 day simple moving average of $0.99. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $3.25. The stock has a market capitalization of $19.44 million, a PE ratio of -0.21 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. As a group, equities research analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in JSPR. Engineers Gate Manager LP acquired a new stake in shares of Jasper Therapeutics in the 4th quarter valued at $26,000. Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics during the 4th quarter worth about $35,000. Acadian Asset Management LLC acquired a new stake in shares of Jasper Therapeutics during the 1st quarter worth about $46,000. Voleon Capital Management LP bought a new position in Jasper Therapeutics during the 3rd quarter valued at about $50,000. Finally, Jain Global LLC bought a new position in Jasper Therapeutics during the 4th quarter valued at about $79,000. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.